Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)

Cadence Pharmaceuticals, Inc. (CADX)

2012 Wedbush PACGROW Life Sciences Management Access Conference

August 14, 2012 1:20 PM EST

Executives

Scott Byrd – SVP and Chief Commercial Officer

Presentation

Richard Lau

Hey guys, I guess we’ll get started here. I am Richard Lau with Wedbush. Introducing today Cadence Pharmaceuticals who launched their drug OFIRMEV about a year and a half ago and on the dollar basis, it’s actually one of the more successful hospital-based launches in recent memory. Here today presenting is Scott Byrd.

Scott Byrd

Good afternoon. I’ll just make one slight adjustment to the introduction. I would say, even on a dollar basis, this is one of the most successful recent hospital product launches and I actually support that with my slides, Richard and we can talk about it as we go. Before I get started certainly refer to our SEC documents for more information about forward -looking statements that I will be making in the course of the presentation.

It has been an exciting time for Cadence this last year and a half. We are hospital focused specialty pharmaceutical company. We have, as you heard, launched our first product OFIRMEV, which is IV acetaminophen. It is a differentiated analgesic. It is a new class in and out of itself for IV pain medications as a non-opioid and non-inside analgesic.

It is designed to be used as the foundation for a multi-modal approach to pain management in the hospital setting and we’ve had really, really nice uptake, not only on the hospital formulary adoption, but the physician feedback and the clinical experience has been really outstanding. We’ll share some of those details in a moment.

If you liked this article you might like

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Mallinckrodt Inks $1.3B Deal for Cadence

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Biotech Stocks Partying Like It's 1999

8 Stocks Under $10 Trending Sharply Higher